Scientists accidentally discovered how an old blood pressure drug hydralazine could fight aggressive brain cancer by ...

Signet Therapeutics founder Haisheng Zhang is betting on organoids and AI to outsmart diffuse gastric cancer and the limits of traditional “clean” drug design.

A Western-led interdisciplinary research team is using artificial intelligence (AI) to target a potentially harmful enzyme found in the human body ...

Scientists accidentally discovered that a common blood pressure drug called hydralazine could actually slow down fast-growing ...

Sometimes big breakthroughs in science come from very small changes, curiosity, and more than a little luck. A new study from ...

A long-trusted blood pressure medication could also show some effect to stop the growth of tumors, found a highly trained ...

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, ...

VANCOUVER, BC / ACCESS Newswire / November 18, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it is initi ...

For rare diseases, AI-driven repurposing fills a critical gap. With more than 7000 rare diseases and only a small percentage ...

One person’s side effect could be another person’s treatment if we expand our perspective on small molecule drug targets, ...

A research team from the Department of Bioscience, Faculty of Life Sciences, Okayama University of Science, has made a discovery: bitter taste receptors are present inside cancer cells and play a ...